Henriette F.
- Country
- Hungary
- Department
- Department of Internal Medicine
Research Overview
- Efficacy and Safety of Deucrictibant for Prophylaxis and On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
- Long‑Term Safety of Repeated Subcutaneous ADX‑324, a Prekallikrein‑Targeting siRNA, in Adults With Hereditary Angioedema: Phase 3 Extension Study
- Evaluation of Long-Term Safety of Oral Deucrictibant (PHA-022121) for Acute Hereditary Angioedema Attacks in C1-Inhibitor Deficient Patients
Data & Insights
Has run more than one trial at 62 of 78 partner sites.
Specializations
Hereditary Angioedema Management
The investigator specializes in the treatment and management of hereditary angioedema (HAE), with particular emphasis on innovative therapeutic approaches for both acute attacks and preventive care.
- Acute Attack Treatment
- Prophylactic Therapy
- Long-term Disease Management
Their research focuses on advancing treatment options for patients with Type I and II HAE variants.
Therapeutic Innovation
The investigator conducts research on novel oral medications for HAE, including extended-release formulations and soft capsule preparations designed for on-demand treatment scenarios.
- Oral Drug Development
- Extended Release Formulations
- Treatment Optimization
Their work encompasses both immediate intervention strategies and long-term therapeutic solutions.
Clinical Applications
The investigator evaluates treatment efficacy across different patient populations, including adolescents and adults, with special attention to symptom relief and attack prevention.
- Symptom Management
- Safety Assessment
- Patient Response Monitoring
Their research includes specific focus on managing laryngeal attacks and various HAE manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.